Brain Tumors/Oncology				
1	Imaging and Neurologic Symptoms after Hematopoietic Stem Cell Transplant in Children	Duke E	Boston	MA
2	Treatment and Revaccination of Children with Paraneoplastic Opsoclonus-myoclonus Syndrome (OMS) and Neuroblastoma: The Memorial Sloan Kettering (MSK) Experience	Patel A	New York	NY
3	Significant Response of a TSC-associated Pediatric Clival Chordoma Treated with Everolimus	Malbari F	Houston	TX
4	Provider Views on Perioperative Steroid use in Newly Diagnosed Pediatric Brain Tumors	Malbari F	Houston	TX
Cognitive/Behavioral Disorders				
5	A Ball, a Stick, a Stopwatch, and a Sharpened Romberg Can be used for the Assessment and Management of Concussion in Pediatric Patients within 8 Weeks of Injury	Brown W	Providence	RI
6	Characterization of Women's Healthcare and Parameters in Patients with Rett Syndrome	Humphrey K	Cincinnati	OH
7	Clinical Characteristics of Dyslexia in Children	Kim SK	Seoul	Korea
8	Spontaneous Third Ventriculostomy in Krabbe Disease	Kim A	Pittsburgh	PA
9	Dissecting the Role of GABAergic Inhibition from Co-transmitting Inhibitory Interneurons in the Olfactory Bulb	Lyons-Warren A	Houston	TX
10	Functional Disorders Present an Excessive Burden to Healthcare Resources	Rao M	Memphis	TX
11	Expanding the Spectrum of TBCK Mutation in Infantile Hypotonia with Psychomotor Retardation	Spivey T	Washington	DC
12	Role of Serotonin in Synaptic Signaling and Plasticity in Tuberous Sclerosis	Srinivasan R	Chicago	IL
13	Cannabidiol use in Autism Spectrum Disorder: Lessons from the Literature	Yang Brown J	Palo Alto	CA
14	Altered Learning Via Imitation in Autism	Zhao Y	Baltimore	MD
15	Epilepsy, Autism Severity and Regression	Ewen J	Baltimore	MD
16	Differing Relationship Between Task-Related TMS and EEG Measures of Cortical Activation in ADHD and Controls	Ewen J	Baltimore	MD
Critical Care				
17	Critical Role for the Thalamus, Corpus Callosum and Basal Ganglia in Pediatric TBI: Results of a Longitudinal Imaging Study	Ashwal S	Loma Linda	CA
18	Factors Influencing Pediatric Recovery from Traumatic Brain Injury	Feldman A	Hershey	PA

19	Association Between Glasgow Coma Scale Scores With and Without the Verbal Component and Intubation in Critically-Ill Children	Girkar U	Sunnyvale	CA
20	Continuous EEG for Seizure Detection in Neonates after Cardiac Bypass without Deep Hypothermic Cardiac Arrest	Levy R	Palo Alto	CA
21	Acute Fulminant Cerebral Edema: A Profile of 5 Pediatric Cases from a Tertiary Care Center	Patterson Gentile C	Philadelphia	PA
22	Too Much of a Good Thing? Cerebral Venous Sinus Thrombosis due to Excessive Milk Intake-Associated Anemia	Siddiqui S	Milwaukee	WI
23	Melanocortin Agonist Reduces Microglial Activation and Neuroinflammation Following Experimental Traumatic Brain Injury	Siebold L	Loma Linda	CA
Demyelinating Disorders				
24	Characteristics of Children with Demyelinating Disorders with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies	Chong J	San Francisco	CA
25	Anxiety, Depression and Fatigue in Youth with Mog-Associated Neuroinflammation: A Preliminary Report	Ciftci-Kavaklioglu B	Toronto	ON
26	Impact of Disease Modifying Therapy on Quality of Life in Pediatric Multiple Sclerosis	Doslea A	Washington	DC
27	Imaging Negative Bilateral Internuclear Ophthalmoplegia (INO) in a 14-year Old Female	Osman M	Boston	MA
28	A Stroke Mimic: MOG Antibody Encephalomyelitis Presenting as Acute Hemiparesis	Tutmaher M	Atlanta	GA
29	Clinical Presentation of Metachromatic Leukodystrophy	Adang L	Philadelphia	PA
30	Revised Identifications Reveals Hundreds of Leukodystrophy Genes	Soderholm H	Salt Lake City	UT
31	High Leukodystrophy Incidence Discovered Using Genomics Database Allele Frequency Determinations	Soderholm H	Salt Lake City	UT
32	A Zebrafish Model of Vanishing White Matter Disease Reveals Novel Pathology Involving Intron Retention, and a Downstream Role for HSPD1 in Myelin Maintenance	Soderholm H	Salt Lake City	UT
Epilepsy				
33	FRRS1L Gene Homozygous Mutation (p.Gly246del) in Puerto Rican Families With Epileptic Encephalopathy and Dyskinetic Movements	Abdelmoumen I	Philadelphia	PA
34	Retrospective Review of EEG Monitoring, Seizure Management, and Outcomes in a Neonatal ICU Over a 2-year Period	Abreu Molnar D	Miami	FL
35	A Complicated Case of Gastroesophageal Reflux	Berry M	Milton	WA

36	Relationships Between Self-Regulation and Quality of Life: Results From a Phase 3 Study of ZX008 (Fenfluramine HCl Oral Solution) in Children and Young Adults With Dravet Syndrome	Bishop K	Muncy	PA
37	One Hundred Consecutive Cases: Lessons Learned Over One Year in a First Time Seizure Clinic	Ananth A	Birmingham	AL
38	A Phase 1, Single-Dose, Open-Label Pharmacokinetic Study to Investigate the Drug-Drug Interaction Potential of ZX008 (Fenfluramine HCl Oral Solution) and Cannabidiol	Boyd B	Emeryville	CA
39	Benign Epilepsy with Centrotemporal Spikes vs Childhood Absence Epilepsy: Differences in Resting State Language Network Functional Connectivity	Calley C	Cincinnati	OH
40	Staged Transarterial Hemispheric Embolization: An Innovative and Effective Treatment Option for Intractable Seizures in Newborns with Hemimegalencephaly	Chang T	Washington	DC
41	ZX008 (Fenfluramine HCl Oral Solution) Significantly Reduces Frequency of Generalized Tonic-Clonic Seizures in Dravet Syndrome: Pooled Analysis from Two Phase 3 Clinical Trials	Devinsky 0	Livingston	NJ
42	Ketogenic Diet for Pharmacoresistent Infantile Spasms	Fedak Romanowski E	Ann Arbor	MI
43	Characteristics of Individuals with Cortical Visual Impairment of Pediatric Onset: An Interim Analysis of a Longitudinal Study	Fisher K	Houston	TX
44	Defining a Minimal Clinically Important Difference in Seizure Frequency Using Data From a Phase 3 Clinical Study of Add-On, Low-Dose ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome Patients Receiving an Antiepileptic Drug Regimen Containing Stiripentol	Gammaitoni A	Emeryville	CA
45	Drug-Drug Interaction (DDI) Studies with Coadministration of Cannabidiol (CBD) and Clobazam (CLB), Valproate (VPA), Stiripentol (STP) or Midazolam (MDZ) in Healthy Volunteers (HVTs) and Adults with Epilepsy	Gidal B	Madison	WI
46	Corticosteroids Reduce Seizures and Improve Diffuse Slowing and Organization Amongst Pediatric Patients with Refractory Epilepsy	Gofshteyn J	New York	NY
47	A Learning Healthcare System for Pediatric Epilepsy: Preliminary Counts	Grinspan Z	New York City	NY
48	The Case for Integrated Behavioral Health in the Management of Adolescent Epilepsy	Harris M	Los Angeles	CA
49	Digital and Technological Opportunities in Epilepsy: A Future Self-Management Ecosystem	Hixson J	San Francisco	CA

50	Developing an Instrument for Screening of Transition Readiness for Adolescents with Epilepsy	Joshi S	Ann Arbor	MI
51	Impact of Epilepsy Surgery on Behavioral and Cognitive Outcomes	Kantamneni T	Sacramento	CA
52	Incidence and Prognosis of Seizures in Patients with Myelomeningocele Over 38 Year Follow Up	Karakas C	Houston	TX
53	Case Report: "The Cat's Out of the Bag,"A Rare Case of New-onset Refractory Status Epilepticus Due to Bartonella Henselae	Kern-Smith E	Atlanta	GA
54	Behavioral and Cognitive Effects of Long-term Adjunctive Brivaracetam in Children with Epilepsy: A Pooled Interim Analysis of Two Open-label Trials	Lagae L	Leuven	Belgium
55	Analysis of a Database of Children with Infantile Spasms in Seizure Tracker (TM)	LaGrant B	New York	NY
56	Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) Enrolled in Three Randomized Controlled Trials	Marsh E	Philadelphia	PA
57	Cannabidiol as a Novel Treatment for Lafora Body Disease – A Case Report	Nayak A	Houston	TX
58	The Effect of Mozart K. 448 Music on Interictal Epileptiform Discharges in Children with Epilepsy: A Randomized Controlled Trial : A Pilot Study	Paprad T	Bangkok	Thailand
59	Risk Factors and Comorbidities in Pediatric Epilepsy in the Seizures and Outcomes Study	Record E	Washington	DC
60	Safety of Valtoco™ (NRL-1; diazepam nasal spray) in Children and Adolescents with Epilepsy: Interim Subgroup Results from a Phase 3, Open-Label, 12-Month Repeat Dose Study	Segal E	Hackensack	NJ
61	Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS) in an Open-Label Extension (OLE) Trial	Shiloh-Malawsky Y	Chapel Hill	NC
62	ZX008 (Fenfluramine HCl Oral Solution) Provides Long-Term, Clinically Meaningful Reduction of Convulsive Seizure Frequency in Young (<6 years old) Dravet Syndrome Subjects: Analysis From Long-Term Open-Label Study	Sullivan J	San Francisco	CA
63	Epilepsy Characterization in a Pediatric Population with Celiac Disease	Swartwood S	Salt Lake City	UT
64	Pharmacokinetics and Safety of Valtoco™ (NRL-1; diazepam nasal spray) in Children with Epilepsy During Seizure (Ictal/peri-ictal) and Non-seizure (Inter-ictal) Conditions: Results from a Phase 1, Open-Label Study	Tarquinio D	Atlanta	GA
65	Ictal "Squeaks": A Newly Described Semiology of Generalized Seizures	Tsuboyama M	Miami	FL
66	Targeted Therapy with Sirolimus for NPRL3 Epilepsy	Vawter-Lee M	Cincinnati	OH

67	Yield of Video EEG Monitoring for Patients Admitted to a Primary Pediatric Neurology Inpatient Service	Wood E	Aurora	CO
68	FIRES: A Case of Immunological Dysregulation?	Yang J	San Diego	CA
69	Collaborating to Improve Epilepsy Surgical Care in Children: The Pediatric Epilepsy Research Consortium (PERC) Surgery Subgroup	Perry M	Fort Worth	TX
70	Cannabidiol (CBD) Significantly Reduces Convulsive Seizure Frequency in Dravet Syndrome: Results of a Dose-Ranging, Multicenter, Randomized, Double-Blind, Placebo-controlled Trial	Perry M	Fort Worth	TX
71	Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS) in an Open-Label Extension (OLE) Trial (GWPCARE5)	Perry M	Fort Worth	TX
72	Prescribing Practices and Antiepileptic Drug Choice in Benign Epilepsy with Centrotemporal Spikes	Hull M	Houston	TX
73	Febrile Infectious Related Epilepsy Syndrome (FIRES) a Description of Two Patients	Kerashvili N	Columbia	SC
Genetics				
74	MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like Episodes) – Case Report and Review of Literature	Kerashvili N	Columbia	SC
75	Truncating Biallelic Variant in DNAJA1 is Associated with Intellectual Disability and Seizures	Alsahli S	Houston	TX
76	Congenital Disorders of Glycosylation : The Saudi Experience	Tabarki B	Riyadh	Saudi Arabia
77	Sepiapterin Reductase Deficiency: Report of 5 New Cases	Alsubhi S	Montreal	QC
78	Lessons from Fetal Medicine: Early Recognition of Pyruvate Dehydrogenase Complex Deficiency	Amin H	Houston	TX
79	Natural History of Canavan Disease: Twenty-three New Cases and Comparison with the Literature	Eichler F	Boston	MA
80	Felbamate Induced Thrombocytopenia in a Previously Nondiagnosed Case of Cornelia de Lange Sequence	Fain D	Grand Rapids	MI
81	Utility of Gene Panel Testing in Children with Seizure Onset after 2 Years of Age: Results from a European and Middle Eastern Epilepsy Genetic Testing Program	Izzo E	Novato	CA
82	Developmental Outcomes of Aicardi Goutières Syndrome	Gavazzi F	Philadelphia	PA
83	Heterogeneity of Neuroimaging and Genotype-phenotype Correlations in Leigh Syndrome	Gordon-Lipkin E	Bethesda	MD

84	Hyperekplexia and Apnea of Infancy as the Initial Presentation of a Novel Variant in SCN8A	Herman I	Houston	TX
85	The c.1353C>G (p.D451E) Variant of SLC6A1 Gene is Associated with Intractable Myoclonic-atonic Epilepsy and Absence Seizures in a Family with Autosomal Dominant Mode of Inheritance	Johnson D	Johnson City	TN
86	Human Genetic Risk and Protective Factors In Congenital Zika Syndrome	Kousa Y	Washington	MD
87	Neurologic Manifestations of Mucopolysaccaridosis Type VI do not Include Intellectual Disability: Reminder to Consider a Second Diagnosis when Faced with Atypical Presentations	Lau H	New York	NY
88	Exome Sequencing in Patients with Cerebral Palsy Identifies an Etiology in One-third of Cases, Underscoring the Need for Broad Genetic Testing and a Significant Recurrence Risk for Families	Millan F	Gaithersburg	MD
89	Novel Variants in Phosphatidylinositol Glycan Anchor Biosynthesis Class G Protein (PIGG) and Mitochondrial Spectrophotometric Analysis Expand the Clinical Spectrum of PIGG-related Disease	Nagy A	Boston	MA
90	Gene Therapy for AADC Deficiency: MRI-Guided Delivery of AAV2-hAADC to the Midbrain	Pearson T	St. Louis	MO
91	A Case of 5,10-methenyltetrahydrofolate Synthetase Deficiency Due to Biallelic Null Mutations with Novel Findings of Elevated Neopterin and Macrocytic Anemia	Romero J	Philadelphia	PA
92	Expanding the Clinical Phenotype of MSTO1-associated Mitochondrial Myopathy	Schultz-Rogers L	Rochester	MN
93	Genetic Test Results for 896 Patients with ASD/ID: The Diagnostic Yield of Multigene Analysis (Autism/ID Xpanded test) is Higher than Conventional First-tier Tests, such as FMR1 Repeat Analysis and Chromosomal Microarray	Shanmugham A	Elmwood Park	NJ
94	Ischemic Stroke in Cockayne Syndrome	Tochen L	Washington	DC
Headache/Migraine				
95	New Persistent Post-Concussion Headache in Children and Adolescents	Barissi M	Grand Rapids	MI
96	Pediatric Screen Exposure and Headache Disability	Langdon R	Washington	DC
97	Using Mobile Technologies to Investigate Proximal Environmental Triggers of Migraine	Lateef T	Washington DC	DC
98	Predictability of Disease Recurrence in Pediatric Primary Intracranial Hypertension Based on Opening Pressure Measurement Prior to Medication Wean	Pabst L	Columbus	OH
99	Headache Frequency in Children After Hemispherectomy	Pandit I	Cleveland	OH
100	New Daily Persistent Headaches in a Pediatric Population	Pierce E	New London	CT

101	Joint Hypermobility and Associated Headache Disability	Sahjwani D	Washington	DC
102	Prognosis of New Daily Persistent Headache in Children and Adolescents	Simmons A	Cleveland	OH
Infections/Neuroimmunology				
103	A Neurodevelopmental Mouse Model of Congenital Zika Virus Infection	Agner S	St. Louis	MO
104	Acute Flaccid Myelitis at a Tertiary Care Institution in Western Pennsylvania	Albashiti B	Pittsburgh	PA
105	NMDA Receptor Encephalitis and Brain Volume Loss in Children, A Quantitative Study	Bassal F	Phoenix	AZ
106	Genetic Mimics of Autoimmune Encephalitis	Calame D	Houston	TX
107	Pediatric Acute Flaccid Myelitis (AFM): Single Institution Experience During 2018 Season	Fisher K	Houston	TX
108	Pediatric Anti-NMDA Receptor Encephalitis: A Case Series	Marcus L	Birmingham	AL
109	Patient Characteristics of Diagnosed Opsoclonus Myoclonus Syndrome at a Single Center	Melendez-Zaidi A	Houston	TX
110	A Histopathologic Review of Post-herpes Simplex Virus Encephalitis with Neurologic Relapse	Mwangi M	St Louis	MO
111	Neurodevelopment in Apparently Normal Newborns from Zika Virus Positive Pregnancies	Mulkey S	Washington	DC
112	Central Nervous System Virus Infection in African Children with Cerebral Malaria	Postels D	Washington	DC
113	Autoimmune Encephalitis in Children: A Case Series at a Tertiary Care Center	Rutatangwa A	San Francisco	CA
114	A Rare Case of an Intramedullary Spinal Cord Abscess Due to Escherichia Coli in a Pediatric Patient	Sehgal R	Maywood	IL
115	Viral Strain Determines Disease Symptoms, Pathology, and Immune Response in a Rat Model of Congenital LCM Virus Infection	Todd D	Iowa City	IA
116	Extended Immunotherapy for Pediatric Anti-NMDAR Encephalitis	Wells E	Washington	DC
Movement Disorders				
117	Management of Life Threatening Movement Disorder in GNAO1 Mutations: Two New Cases and Review of the Literature	Hull M	Houston	TX
118	Cerebral Palsy Spectrum Disorder in Canadian Indigenous Children	Chen A	Montreal	QC
119	Losing a Diagnosis of Cerebral Palsy: Comparison of Characteristics at Age 2 Between Eventual Confirmed and Non-Confirmed Cerebral Palsy at Age 5	Chen A	Montreal	QC
120	Pain and Sensory Features in Individuals with Cerebral Palsy	Chin E	Baltimore	MD
121	Methyldopa Causing Parkinsonism in a Young Adult	Fraser S	Houston	TX

122	Striatal Interneurons are Increased or Selectively Preserved in Dystonic Rats Following Neonatal Brain Injury	Gandham S	St. Louis	MO
123	The Natural History of AADC Deficiency: A Retrospective Study	Gilbert L	St. Louis	MO
124	Quantification of the General Movement Assessment Using Center of Pressure Patterns in Healthy Infants	Kapil N	Little Rock	AR
125	A Novel DYT1A Mutation Associated with Secondary Tic Disorder	Kaul S	Houston	TX
126	Lower Limb Injections of OnabotulinumtoxinA: Improvement in Gait and Treatment Goal Achievement in Pediatric Patients with Cerebral Palsy	Kim H	St. Louis	MO
127	Ataxic-Hypotonic Cerebral Palsy in a Cerebral Palsy Registry: Insights into a Distinct Subtype	Levy J	Montreal	QC
128	Long-term Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Upper Limb Spasticity in Children With Cerebral Palsy: Open-label Extension Study	McCusker E	Irvine	CA
129	Long-term Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children With Cerebral Palsy: Open-label Extension Study	Meilahn J	Marshfield	WI
130	"Your Child has Cerebral Palsy:" Parental Understanding and Misconceptions	Mohanty M	Boston	MA
131	Deep Brain Stimulation for Pediatric Dystonia	Tsering D	Washington	DC
132	GNAO1 Associated Neurologic Disease: Results from the 1st Annual Research Clinic	Viehoever A	St. Louis	MO
133	Striatal Cholinergic Interneurons may Play Different Roles in Dystonia Pathogenesis Across Development	Aravamuthan B	St. Louis	MO
Neonatal Neurology				
134	Sexual Dichotomy in Outcomes Following Neonatal Brain Injury in Rats	Aravamuthan B	St. Louis	MO
135	Hospitalizations in School Aged Children with Cerebral Palsy: A Nested Case Control Study	Fortin O	Montreal	QC
136	Emergency Department Use in Children with Cerebral Palsy: A Nested Case Control Study	Fortin O	Montreal	QC
137	Neurodevelopmental Outcomes in Infants with Congenital Zika Virus Exposure: Data from a Prospective Cohort in Vitoria, Brazil	Chamberlain L	Durham	NC
138	Epilepsy Outcomes in Mild, Moderate, and Severe Hypoxic-ischemic Encephalopathy (HIE)	DeLaGarza-Pineda O	Monterrey	Mexico
139	Characteristics of Neonatal Seizures Related to Intracranial Hemorrhage in Term Neonates: A Study of the Neonatal Seizure Registry	Herzberg E	Boston	MA

140	Clinical Presentation, Neuroimaging Features and Long-term Outcome in Neonatal Cerebral Sinus Venous Thrombosis: A Retrospective Analysis	Karakas C	Houston	TX
141	Association of Circulating Pro- and Anti-inflammatory Protein Biomarkers in the First Two Postnatal Weeks with Brain MRI Volumes and Cognitive Function at Age 10 Years in Extremely Preterm Born Children	Kuban K	Boston	MA
142	When EEG is Not Enough: Catching Intracranial Hemorrhage in Infants with Spells using the Pittsburgh Infant Brain Injury Score	Ortman C	Pittsburgh	PA
143	Utility of aEEG for Seizure Screening in Three Clinical Scenarios	Sandoval Karamian A	Palo Alto	CA
144	Fetal Neurology Consultations: A Single Institution Experience	Sharp A	Baltimore	MD
145	A "Biomarker" that Predicts Responsiveness to Stem Cell Therapy Based on Mechanism-of-action: Evidence from Imaging Neonatal Rat Brain Hypoxic-ischemic Injury	Ashwal S	Loma Linda	CA
146	Intracranial Hemorrhage in Term Neonates: An Institutional Perspective	Yang Brown J	Palo Alto	CA
147	Two cases of Neonatal Arterial Ischemic Stroke in the setting of Neonatal Alloimmune Thrombocytopenia (NAIT)	Osman M	Boston	MA
148	Pilot Study of Prenatal Hypoxia-exposed Mice Reveal Potential Sex-dependent Differences in Anxiety-related Behaviors	Cristancho A	Philadelphia	PA
Neuroimaging				
149	Characterization of Features of PHACE Syndrome on Fetal MRI and Natural History of Postnatal Management	Cristancho A	Philadelphia	PA
150	Altered Cortical Development in Living Fetuses with Dandy-Walker Malformation	Akiyama S	Sendai	Japan
151	Validation of Breath-Hold Cerebrovascular Reactivity Imaging in Healthy Children	Alhadid K	Toronto	ON
152	Acute and 1-Year Susceptibility Weighted MRI After Pediatric TBI: Relationship of Lesion Load, Regional Distribution and Resolution of Traumatic Cerebral Microbleeds; to Neurological and Neuropsychological Outcomes	Ashwal S	Loma Linda	CA
153	Static and Dynamic Organization of EEG Oscillations During a Visual-Motor Task: A Developmental Perspective	Chin E	Baltimore	MD
154	Tubers Associated with Infantile Spasms Impact a Common Brain Network in Tuberous Sclerosis Complex	Cohen A	Boston	MA
155	Deep Learning Model of Ventricle Volume Predicts Developmental Outcomes in Prematurity	Han M	Palo Alto	CA

156	Lenti-D Gene Therapy Attenuates Microvascular Perfusion Abnormalities and Halts Cerebral Adrenoleukodystrophy Lesion Progression	Musolino P	Boston	MA
157	Chronic Subdural Hygroma in Suspected Abusive Head Trauma	Scheller J	baltimore	MD
158	Fetal Diagnosis of Posterior Fossa Abnormalities is Enhanced by Fetal MRI	Schlatterer S	Washington	DC
159	Quantitative MRI Analyses of Regional Brain Growth and Cerebral Sulcal Development in Living Fetuses with Down Syndrome and Isolated Ventriculomegaly	Tarui T	Boston	MA
160	Quantitative Fetal MRI Measures of Isolated Cerebral Ventriculomegaly Associated with Postnatal Neurodevelopmental Outcomes	Tarui T	Boston	MA
161	Giant Tumefactive Perivascular Spaces in a Pediatric Patient with Neurofibromatosis Type-2	Tittle B	Wauwatosa	WI
Neuromuscular Disorders				
162	Incidentally Identified Duplication on Xp21.1 Encoding the Dystrophin Gene in a 5 Year Old Boy with Normal Creatine Kinase (CK)	Osman M	Boston	MA
163	Nusinersen Improves Motor Function which Correspond to Improved Swallowing, Body Mass Index, Pulmonary Function Tests, Sleep and Decreased Requirement of Mechanical Ventilation	Arya K	Little Rock	AR
164	HUI, WPAI, and Neuromuscular PedsQL Scores in Patients with Spinal Muscular Atrophy: Findings from the 2019 Cure SMA Community Update Survey	Belter L	Elk Grove Village	IL
165	Nusinersen in Infants who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy: Interim Results from the Phase 2 NURTURE Study	Butterfield R	Salt Lake City	UT
166	Interim Report on the Safety and Efficacy of Longer-term Treatment with Nusinersen in Later-onset Spinal Muscular Atrophy (SMA): Results from the SHINE Study	Chiriboga C	New York	NY
167	Genotypic and Sociodemographic Associations with Increased Age of Diagnosis in Patients with Duchenne Muscular Dystrophy without a Known Family History	Counterman K	Boston	MA
168	Assessment of Awareness of the Early Clinical Features of Spinal Muscular Atrophy (SMA) Amongst Pediatricians	Curry M	Chicago	IL
169	Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update	Day J	Stanford	CA
170	Adeno-Associated Virus Serotype 9 (AAV9) Antibodies in Patients With Spinal Muscular Atrophy (SMA) Screened for Treatment With Gene-Replacement Therapy (GRT) Onasemnogene Abeparvovec	Day J	Stanford	CA
171	A Child with Congenital Lambert-Eaton-like Myasthenia Syndrome	DiMario Jr. F	Hartford	CT

172	Burden of Illness of Spinal Muscular Atrophy Type 1 (SMA1)	Droege M	Bannockburn	IL
173	Association Between Plasma Phosphorylated Neurofilament Heavy Chain and Efficacy Endpoints in the Nusinersen NURTURE Study	Finkel R	Orlando	FL
174	Interim Report on the Safety and Efficacy of Longer-term Treatment with Nusinersen in Infantile-onset Spinal Muscular Atrophy (SMA): Updated Results from the SHINE Study	Finkel R	Orlando	FL
175	Rituximab as Immunomodulatory Agent in Pre-adolescent Pediatric Onset Isaacs' Syndrome: Case Report of Favorable Longitudinal Response	Fisher K	Houston	TX
176	Erythromelalgia in Children: A Single Center Experience	Ghosh D	Cleveland	OH
177	Mini-COMET Study: Safety Data and Immunogenicity for Repeat Avalglucosidase Alfa Dosing in Patients with Infantile-onset Pompe Disease who were Previously Treated with Alglucosidase Alfa and Demonstrated Clinical Decline	Hug C	Cambridge	MA
178	Anti-MuSK Antibody-positive Ocular Myasthenia Gravis	Yu J	Cheonan	Korea
179	The AveXis, Inc. Managed Access Program (MAP): Single-Patient Investigational New Drug (IND) Requests for Gene-Replacement Therapy (GRT) Onasemnogene Abeparvovec for Spinal Muscular Atrophy (SMA)	Kichula E	Philadelphia	PA
180	Cost-Utility and Budget Impact Analyses of One-Time Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 Compared to Chronic Nusinersen Treatment	Malone D	Tucson	AZ
181	Comparing Hospital Respiratory Outcomes Pre- and Post- Nusinersen Treatment in Children with Spinal Muscular Atrophy (SMA)	Matesanz S	Philadelphia	PA
182	Preservation of Function over time as Measured by North Star Ambulatory Assessment in Ambulatory Boys with Nonsense Mutation Muscular Dystrophy Treated with Ataluren	McDonald C	Sacramento	CA
183	Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2a Clinical Trial	Mendell J	Columbus	OH
184	Timed-function Test Data in Patients with Duchenne Muscular Dystrophy from the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and the CINRG Natural History Study: A Matched Cohort Analysis	Mercuri E	Rome	Italy
185	Age at Loss of Ambulation in Patients with Duchenne Muscular Dystrophy from the STRIDE Registry and the CINRG Natural History Study: A Matched Cohort Analysis	Muntoni F	London	UK

186	Two Phase 2 Trials to Assess Production of Dystrophin in Patients with Nonsense Mutation Duchenne Muscular Dystrophy Receiving Ataluren	Nelson S	Los Angeles	CA
187	Dystrophin Restoration by Exon 53 Skipping in Patients with Duchenne Muscular Dystrophy after Viltolarsen Treatment: Phase 2 Study Update	Rao V	Chicago	IL
188	Systemic Gene Transfer with rAAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients with Limb Girdle Muscular Dystrophy Type 2E	Rodino-Klapac L	Cambridge	MA
189	Deflazacort or Prednisone Treatment for Duchenne Muscular Dystrophy: A Meta-analysis of Disease Progression Rates in Two Multicenter Clinical Trials	Signorovitch J	Boston	MA
190	The Therapeutic Effect of Myostatin Oral Vaccine in Duchenne Muscular Dystrophy Mouse Model	Sung DK	Seoul	Korea
191	Pulmonary Function in Patients with Duchenne Muscular Dystrophy from the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and the CINRG Natural History Study: A Matched Cohort Analysis	Tulinius M	Gothenborg	Sweden
192	Plectinopathies Causing Congenital Myasthenic Syndrome (CMS): A Case Study and Review of Literature	Tutmaher M	Atlanta	GA
193	Intrathecal Nusinersen in Older Children and Adults with Spinal Muscular Atrophy	Veerapandiyan A	Little Rock	AR
194	Dilated Cerebral Arteriopathy in Pompe's Disease	Viamonte M	Gainesville	FL
195	Compound Heterozygous CACNA1H Mutations Associated with Severe Congenital Amyotrophy	McMillan H	Ottawa	ON
196	Drisapersen Associated with Elevated Factor VIII and von Willebrand Factor in Duchenne Muscular Dystrophy	McMillan H	Ottawa	ON
197	Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series	Schultz M	Bannockburn	IL
198	Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) in Pre-symptomatic Spinal Muscular Atrophy (SMA)	Schultz M	Bannockburn	IL
199	The Value of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Improved Survival, Pulmonary and Nutritional Support, and Motor Function with Decreased Hospitalization	Dabbous O	Bannockburn	IL
200	Event-Free Survival and Motor Milestone Achievement Following Onasemnogene Abeparvovec and Nusinersen Interventions Contrasted to Natural History for Spinal Muscular Atrophy Type 1 (SMA1) Patients	Dabbous O	Bannockburn	IL
Rare Diseases				

201	Economic Burden of Care and Treatment Options for Patients with Rett Syndrome: Two Systematic Literature Reviews	Dabbous O	Bannockburn	IL
202	Intrathecal VTS-270 For The Treatment of Niemann-Pick Disease, Type C1	Berry-Kravis E	Chicago	IL
203	Impact of Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin (HP-B-CD, VTS-270) on Cognitive Decline in Niemann-Pick Type C1 (NPC1)	Berry-Kravis E	Chicago	IL
204	Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease	de los Reyes E	Columbus	OH
205	Intracerebroventricular Cerliponase Alfa for CLN2 Disease: Clinical Practice Considerations from US Clinics	de los Reyes E	Columbus	OH
206	Child Neurology Cases at the NIH-Undiagnosed Diseases Program: 2008-2019	Acosta M	Bethesda	MD
207	AGIL-AADC Gene Therapy Results in Sustained Improvements in Motor and Developmental Milestones through 5 Years in Children with AADC Deficiency	Chien YH	Taipei	Taiwan
208	Delays in Diagnosis are Associated with Poor Clinical Outcomes in Patients with Arginase 1 Deficiency	Diaz G	New York	NY
209	Diagnosis and Treatment of Spinal Muscular Atrophy: Online, Case-based Education Successfully Improved Knowledge and Competence of Neurologists and Pediatricians	Finnegan T	Glenside	PA
210	Development and Reliability of a Scale for Neurologic Function in Children with Aicardi Goutieres Syndrome	Gavazzi F	Philadelphia	PA
211	Neurological Manifestations of TANGO2-Related Metabolic Encephalopathy and Arrhythmias in Children	Hannibal M	Ann Arbor	MI
212	Early Epileptic Encephalopathy, Hypotonia, and Liver Dysfunction caused by D-bifunctional Protein Deficiency	Herman I	Houston	TX
213	Epidemiology, Molecular Genetics, and New Treatment Options for Aromatic Amino Acid Decarboxylase Deficiency	Himmelreich N	Heidelberg	Germany
214	An Observational Study of Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Cerebral Adrenoleukodystrophy (CALD)	Kenney-Jung D	Minneapolis	MN
215	Patient Advocacy Leadership in Advancing Clinical Recommendations in Ultra-Rare Disease: The CLN1 Batten Disease Experience	King S	Charlotte	NC
216	A Multi-Center, Multi-National Retrospective and Prospective Natural History Study of Canavan Disease	Lau H	New York	NY
217	Improved Myoclonus and Seizure Control and Dramatic Improvement of Neurological Function in Patients with Dentatorubral Pallidoluysian Atrophy (DRPLA) Treated with Perampanel	Lewis C	Chapel Hill	NC

218	Deflazacort or Prednisone Treatment for Duchenne Muscular Dystrophy (DMD): Real-world Outcomes at Cincinnati Children's Hospital Medical Center (CCHMC)	Marden J	Boston	MA
219	Progression of Cervical Stenosis in Children Treated with Stem Cell Transplant for Mucopolysaccharidosis Type 1	Mathias S	Minneapolis	MN
220	Clinical and Biomarker Results from an Observational Trial in Niemann Pick Type C Patients	Mengel E	Mainz	Germany
221	From Bench to Bedside: Gene Therapy for Batten (CLN6) Disease	Meyer K	Columbus	OH
222	The Clinical Features, Investigation, Genetic Profiles and Management of Pediatric Hereditary Spastic Paraplegia	Palanisamy D	Cleveland	OH
223	A Study to Asses the Inter- and Intra-rater Reliability of the 5-Domain NPCCSS	Patterson M	Rochester	MN
224	Clinical and Neuroimaging Features of Labrune Syndrome (Leukoencephalopathy with Calcifications and Cysts)	Rhee J	Washington	DC
225	Cerliponase Alfa for the Treatment of CLN2 Disease in an Expanded Patient Cohort Including Children Younger than Three Years: Interim Results from an Ongoing Clinical Study	Schulz A	Hamburg	Germany
226	Suicide Screening in Sturge-Weber syndrome Versus General Neurology Clinic	Sebold A	Baltimore	MD
227	Diagnosing and Managing A Rare Case of Late-infantile GM1-Gangliosidosis: A Case Report	Shekar S	New Brunswick	NJ
228	Wearable Sensors Detect Impaired Balance and Coordination in LBSL During Remote, Home-Based Assessments	Smith Fine A	Baltimore	MD
229	Progression of Cerebral Lesion Patterns in Patients with ACTA2 Arginine 179 Gene Mutation	Speroni S	Boston	MA
230	Sudden Painless Right Arm Weakness in a 2 Year Old Male-A Case Presentation and Literature Review	Tunc E	Cleveland	OH
231	Safety and Improved Efficacy Outcomes in Children with AADC Deficiency Treated with AGIL-AADC Gene Therapy: Results from Three Clinical Trials	Hwu P	Taipei	Taiwan
232	Two Novel RARS2 Mutations in Two Siblings with Pontocerebellar Hypoplasia Type 6 Presenting as Early Epileptic Encephalopathy	Xiao W	New York	NY
233	Evolution of Radiographic Abnormalities Distinguishes Isolated Sulfite Oxidase Deficiency and Molybdenum Cofactor Deficiency from Neonatal Hypoxic Ischemic Encephalopathy	Misko A	Boston	MA
234	Cross Sectional Observations on the Natural History of Mucolipidosis Type IV Reveal Extrapyramidal Signs and Progressive Pyschomotor Decline	Misko A	Boston	MA

Stroke				
235	Retrospective Chart Review: Pediatric Demographics in Children Presenting with Acute Neurological Deficit Concerning for Acute Ischemic Stroke: An Evaluation of the Stroke Alert Process	Barkley T	Kansas City	MO
236	Radiographic Patterns of Injury and Risk Factors in Children with Hemiplegic Cerebral Palsy	Domi T	Toronto	ON
237	Neuroplasticity Following Early Childhood Brain Injury Supports Language Development	Emami Z	Toronto	ON
238	Mechanical Thrombectomy in Pediatric Stroke: Report of Three New Cases and a Review of the Literature	Gervelis W	Indianapolis	IN
239	Creation of a Suspected Stroke Protocol: Streamlining Evaluation and Diagnosis of Children with a Focal Neurological Deficit	Goeden M	Kansas City	KS
240	Expanding the Clinical and Radiological Phenotype of Mineralizing Angiopathy and Pediatric Stroke – A 15 Year Single-center Experience	Gorodetsky C	Toronto	ON
241	Variability in Thrombolytic and Endovascular Therapy use in Pediatric Stroke: A Cross-Sectional Survey	Grewal P	Lexington	KY
242	Concordance of Blood-brain Barrier Permeability Measures in a Juvenile Rat Model of Photothrombotic Stroke	Honarvar F	Toronto	ON
243	Clinical Phenotypes of Pediatric Moyamoya: Clinical and Radiographic Characteristics at Presentation	Kaseka M	Toronto	ON
244	A Multisite Blinded Comparative Efficacy Trial of CIMT Dose Levels and Constraint Variations for 2 – 8 Year Olds with Hemiparetic Cerebral Palsy	Ramey S	Roanoke	VA
245	Retrospective Study of Moyamoya Disease in a Pediatric Cohort	Rodriguez D	Phoenix	AZ
246	Perinatal Strokes and Hemiplegic Cerebral Palsy: Associated Factors from a Controlled National Registry Cohort	Vitagliano M	Montreal	QC
247	Trends in Pediatric Acute Stroke Protocol Utilization over 7 Years	Wharton J	Nashville	TN
248	A Retrospective Analysis of Clinical Features, Neuroimaging Findings and Long-term Outcome in Pediatric Cerebral Venous Sinus Thrombosis	Karakas C	Houston	TX

Teaching of Child Neurology				
249	Quality of Life in Individuals with Syndromic Autism Spectrum Disorders	Andujar F	Houston	TX
250	Quality Improvement Strategies Improve Pediatric Neurology Inpatient Discharges Before Noon	Eksambe P	Glen Oaks	NY
Translational/Experimental Therapeutics				
251	Lentiviral (LV) Hematopoietic Stem Cell Gene Therapy (HSC-GT) for Metachromatic Leukodystrophy (MLD) Provides Sustained Clinical Benefit	Fumagalli F	Milan	Italy
252	Differences in Health-Related Quality of Life, Self-Management, & Self-Efficacy Between Children with Neurological Conditions and Other Chronic Illness & Medical Complexity	Reyes B	Los Angeles	CA
ACNN				
253	Insular Epilepsy	Michon A	Royal Oak	MI
254	Managing Students with Seizures ECHO: The Importance of School Nurses	Schultz R	Houston	TX
255	Implementation of Building the M-CHAT-R Into the Electronic Medical Record	Fisher B	Chicago	IL
Late Breaking Abstracts				
256	Lenti-D Hematopoietic Stem Cell Gene Therapy Stabilizes Neurologic Function in Boys with Cerebral Adrenoleukodystrophy	McNeil E	Cambridge	MA
257	De Novo EIF2AK1 and EIF2AK2 Variants are Associated with Developmental Delay, Movement Disorders, Cerebellar Ataxia, Leukoencephalopathy, and Neurologic Decompensation	Chao H-T	Houston	TX
258	Chimeric Antigen Receptor (CAR) T Cell Neurotoxicity Correlates with Pretreatment and Acute CSF Neurofilament Light Chain (NFL) Levels	Gust J	Seattle	WA
259	The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)	Escolar M	Pittsburgh	PA
260	First-In-Human Intrathecal Gene Transfer Study for Giant Axonal Neuropathy: Three-Year Study Review of Safety, Immunologic Responses and Interim Analysis of Efficacy	Bharucha-Goebel D	Washington	DC